Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
27 avr. 2022 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021
07 janv. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments
12 nov. 2020 16h05 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Appoints Three New Members to its Board of Directors
25 sept. 2020 08h00 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Announces Pricing of Upsized Initial Public Offering
24 sept. 2020 20h12 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Appoints Robert Breuil as Chief Financial Officer
04 sept. 2020 07h00 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical Officer
18 mai 2020 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., May 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening...
Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months
18 mars 2020 07h00 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the...
Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting
28 févr. 2020 07h00 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic...